Drug facts

Tirzepatide and alcohol

Reviewed August 2026

What the label says about drinking: nothing¹

Alcoholic drinks are not mentioned anywhere in the 4/2026 revision of the prescribing information: not in the warnings and precautions, not in either drug-interaction subsection, not in the patient counseling information, and not in the Medication Guide bound to it. That is the entire document, which is what makes the absence worth telling you about. The only occurrence of “drink” in it is an instruction, in the Medication Guide, to drink fluids to reduce the chance of dehydration.

Section 7 has exactly two entries, and neither concerns alcohol. Section 7.1 covers concomitant use with insulin or an insulin secretagogue. Section 7.2 covers oral medications, because tirzepatide delays gastric emptying and can therefore affect how they are absorbed — the reason the label singles out drugs with a narrow therapeutic index and oral hormonal contraceptives. Those two entries are the label’s complete account of what this drug interacts with.

An absence is only as good as the document behind it. This one comes from the manufacturer’s own posted label, read on the day shown, rather than from a summary of it — the standard set out in how we verify what goes on a page.

The only alcohol on the label is an ingredient²

Section 11 lists what is in each presentation, and this is where the word actually appears. The single-dose pen and single-dose vial contain sodium chloride, sodium phosphate dibasic heptahydrate and water for injection — no benzyl alcohol. The multi-dose vial and the single-patient-use pen do contain it, at 5.4 mg per dose, alongside glycerin and phenol.

It is a preservative, not a reason to think about drinking. It is worth knowing only because a compounded vial is typically a multi-dose vial, and preservative content is one of the things that genuinely varies between preparations — part of what is actually different between a compounded vial and Zepbound.

What the label does document³

Three of the label’s warnings are the ones a prescriber will be weighing when someone asks this question. Stating them is not the same as saying alcohol affects them, and the label does not say that.

Hypoglycemia (5.7)

Tirzepatide lowers blood glucose and can cause hypoglycemia. In the trial of participants with type 2 diabetes, plasma glucose below 54 mg/dL was reported in 4.2% of treated participants against 1.3% on placebo, and in 10.3% of those also taking an insulin secretagogue against 2.1% of those who were not.

Acute kidney injury from volume depletion (5.3)

Postmarketing reports of acute kidney injury, in some cases requiring hemodialysis. The majority occurred in patients who had gastrointestinal reactions leading to dehydration.

Acute pancreatitis (5.5)

Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists or with this product.

Each of those is a documented risk of the drug. Whether any of them interacts with a person’s drinking is a question about that person — their other medications, their liver, their history — and it is answerable only by someone who has that information. The rest of the label’s risk profile sits on the reactions reported in 5% or more of participants.

The other direction: does tirzepatide change drinking?⁴

This is the question the research has actually looked at, and the honest summary is short: no randomized trial of tirzepatide has measured it.

The most-cited tirzepatide-specific report is a 2023 paper in Scientific Reports with two parts. The first was a machine-learning analysis of roughly 68,250 Reddit posts about GLP-1 and GLP-1/GIP agonists, of which 1,580 mentioned alcohol. The second recruited 153 people with a BMI of 30 or above who self-reported either taking semaglutide, taking tirzepatide, or taking neither, and compared self-reported drinking. It found lower self-reported intake, fewer drinks per drinking episode, lower odds of binge drinking and lower AUDIT scores in the medication group.

Every part of that is self-reported and none of it is randomized: participants chose their own medication, reported their own dose status and reported their own drinking. The authors describe it as initial real-world evidence, and that is the right weight to give it. It is not a trial result, and it should not be read as one.

There is a randomized trial in this area, and it is of a different drug. A 2025 phase 2 trial in JAMA Psychiatry randomized 48 non-treatment-seeking adults with alcohol use disorder to nine weeks of low-dose semaglutide or placebo. It reduced the amount of alcohol consumed in a laboratory self-administration task, drinks per drinking day and weekly craving, but did not change average drinks per calendar day or the number of drinking days. Its own conclusion calls this initial prospective evidence justifying larger trials.

Semaglutide is not tirzepatide, 48 participants is not a definitive sample, and nine weeks is not a year. It is here because it is the strongest evidence anywhere near this question, and leaving it out would make the evidence look thinner than it is.

1. Quddos F, Hubshman Z, Tegge A, et al. Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity. Sci Rep. 2023 Nov 28. PMID 38017205.
2. Hendershot CS, Bremmer MP, Paladino MB, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025 Apr 1;82(4):395-405. PMID 39937469. NCT05520775.

What a compounded vial changes¹

Where to take this⁵

To a prescriber, and it is a reasonable thing to raise at the first appointment rather than after. The label leaves this question open, which means the answer for any individual depends on facts about that individual — and a website comparing prices is not in a position to know them. If your question is really about feeling wiped out rather than about drinking, see what the label reports about fatigue.